ERBB2 and breast cancer: Since 71.9% of the HER2‐negative breast cancers in our study presented high Ki‐67 expression and HR negativity, these tumors were highly invasive and compressed surrounding tissues during infiltration, which altered hemodynamics and remodeled vessels, accelerating the transit time of the contrast agent.